Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00042471 · ClinicalTrials.gov registry record · Phase 2

Evaluation of the Bioavailability of Pramlintide

A Phase 2 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
75
Enrollment target

NCT00042471: Completed Phase 2 study, sponsored by AstraZeneca.

NCT00042471 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00042471, a Phase 2 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
75 participants
Enrollment target

Study Summary

This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.

Primary Outcome

To determine the effect of various anatomical injection sites and varying needle lengths upon the absolute bioavailability of pramlintide when injected subcutaneously (SC) in non-obese and obese subjects with type 1 and type 2 diabetes mellitus using insulin.

Interventions

  • DRUG Pramlintide acetate

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2002-06
Est. Completion 2002-12
Phase Phase 2
AstraZeneca

1,285 total trials

What the finished NCT00042471 record still lists

NCT00042471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 1 intervention - of which Pramlintide acetate is the first listed.

NCT00042471 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00042471 about?

NCT00042471 is a clinical study titled "Evaluation of the Bioavailability of Pramlintide". This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.

What is the current status of trial NCT00042471?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2002-06. Estimated completion is 2002-12.

What interventions are being tested in trial NCT00042471?

The interventions under investigation include: Pramlintide acetate (DRUG).

Who is sponsoring clinical trial NCT00042471?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00042471's enrollment target sits among peer trials

75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00042471, the US trial registry maintained by the National Library of Medicine. NCT00042471 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.